</iframe<br /><div class="kleanity-single-article-content"><p>JERUSALEM, Dec. 20, 2013 /PRNewswire/ — Oramed Pharmaceuticals Inc. (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today successful results in a clinical trial testing the pharmacokinetic dose response of its oral insulin capsule (ORMD-0801) in type 1 diabetes patients.</p> <p>Patients were treated with a different dose of oral insulin at each study visit; blood glucose and insulin levels were then monitored for the ensuing five hours. Patient responses positively correlated with administered doses, as did the duration of the effect.</p> <p>“Based on these and the notable results from our previous oral insulin trials in type 1 diabetes, we continue to move forward with this indication in parallel to our advanced clinical studies in type 2 diabetes,” commented CEO Nadav Kidron.</p> <p>Type 1 diabetes (T1DM) is an autoimmune disease wherein the body destroys its own insulin-producing cells, leaving patients completely dependent on external insulin sources. The disease, formerly known as juvenile diabetes, currently affects both young and adult populations. According to the International Diabetes Federation, T1DM is on the rise at a rate of 3% per year and currently affects approximately 36 million people worldwide – about 10% of the global diabetes population. The disease was formerly known as juvenile diabetes, and currently affects both young and adult populations.</p> <p>About ORMD-0801 Oral Insulin and T1DM</p> <p>T1DM is currently treated with two types of insulin replacement therapies: long-acting insulin (basal) to help maintain stable insulin levels during fasting periods, and pre-meal insulin (bolus) doses. Oramed proposes to introduce ORMD-0801 to replace the mealtime (bolus) insulin doses, which would significantly reduce the number of daily injections. Additionally, oral administration offers the benefit of reduced systemic exposure and may enable tighter regulation of blood sugar levels by directly affecting glucose control in the liver. For more information on ORMD-0801, the content of which is not part of this press release, please visit http://oramed.com/index.php?page=14</p> <p>About Oramed Pharmaceuticals</p> <p>Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top research scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), which has been assessed in healthy volunteers (Phase 1b) and is currently being tested in T2DM patients (Phase 2a). Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company’s corporate and R&D headquarters are based in Jerusalem.</p> <p>For more information, the content of which is not part of this press release, please visit www.oramed.com</p> </div> </div><!-- kleanity-single-article --> </article><!-- post-id --> </div></div></div></div></div><div class="gdlr-core-page-builder-body"></div><div class="kleanity-bottom-page-builder-container kleanity-container" ><div class="kleanity-bottom-page-builder-sidebar-wrap kleanity-sidebar-style-none" ><div class="kleanity-bottom-page-builder-sidebar-class" ><div class="kleanity-bottom-page-builder-content kleanity-item-pdlr" ><div class="kleanity-single-social-share kleanity-item-rvpdlr" ><div class="gdlr-core-social-share-item gdlr-core-item-pdb gdlr-core-center-align gdlr-core-social-share-left-text gdlr-core-item-mglr gdlr-core-style-plain" style="padding-bottom: 0px ;" ><span class="gdlr-core-social-share-count gdlr-core-skin-title" ><span class="gdlr-core-count" >0</span><span class="gdlr-core-suffix" >Shares</span><span class="gdlr-core-divider gdlr-core-skin-divider" ></span></span><span class="gdlr-core-social-share-wrap"><a class="gdlr-core-social-share-facebook" href="https://www.facebook.com/sharer/sharer.php?caption=ORMP+Results+from+Ex-US+Pharmacokinetic+Study+of+its+Oral+Insulin+for+Type+1+Diabetes&u=https://www.corporateprofile.com/2013/12/23/ormp-results-from-ex-us-pharmacokinetic-study-of-its-oral-insulin-for-type-1-diabetes/" target="_blank" onclick="javascript:window.open(this.href,'', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=602,width=555');return false;" ><i class="fa fa-facebook" ></i></a><a class="gdlr-core-social-share-linkedin" href="http://www.linkedin.com/shareArticle?mini=true&url=https://www.corporateprofile.com/2013/12/23/ormp-results-from-ex-us-pharmacokinetic-study-of-its-oral-insulin-for-type-1-diabetes/&title=ORMP+Results+from+Ex-US+Pharmacokinetic+Study+of+its+Oral+Insulin+for+Type+1+Diabetes" target="_blank" onclick="javascript:window.open(this.href,'', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=452,width=550');return false;" ><i class="fa fa-linkedin" ></i></a><a class="gdlr-core-social-share-google-plus" href="https://plus.google.com/share?url=https://www.corporateprofile.com/2013/12/23/ormp-results-from-ex-us-pharmacokinetic-study-of-its-oral-insulin-for-type-1-diabetes/" target="_blank" onclick="javascript:window.open(this.href,'', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=614,width=496');return false;" ><i class="fa fa-google-plus" ></i></a><a class="gdlr-core-social-share-pinterest" href="http://pinterest.com/pin/create/button/?url=https://www.corporateprofile.com/2013/12/23/ormp-results-from-ex-us-pharmacokinetic-study-of-its-oral-insulin-for-type-1-diabetes/" target="_blank" onclick="javascript:window.open(this.href,'', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=553,width=750');return false;" ><i class="fa fa-pinterest-p" ></i></a><a class="gdlr-core-social-share-twitter" href="https://twitter.com/intent/tweet?text=ORMP+Results+from+Ex-US+Pharmacokinetic+Study+of+its+Oral+Insulin+for+Type+1+Diabetes&url=https://www.corporateprofile.com/2013/12/23/ormp-results-from-ex-us-pharmacokinetic-study-of-its-oral-insulin-for-type-1-diabetes/" target="_blank" onclick="javascript:window.open(this.href,'', 'menubar=no,toolbar=no,resizable=yes,scrollbars=yes,height=255,width=555');return false;" ><i class="fa fa-twitter" ></i></a></span></div></div><div class="clear"></div><div class="kleanity-single-author" ><div class="kleanity-single-author-wrap" ><div class="kleanity-single-author-avartar kleanity-media-image"><img alt='' src='https://secure.gravatar.com/avatar/ff1ea611cbe92c4d272261022142ac70?s=90&d=mm&r=g' srcset='https://secure.gravatar.com/avatar/ff1ea611cbe92c4d272261022142ac70?s=180&d=mm&r=g 2x' class='avatar avatar-90 photo' height='90' width='90' /></div><div class="kleanity-single-author-content-wrap" ><div class="kleanity-single-author-caption kleanity-info-font" >About the author</div><h4 class="kleanity-single-author-title"><a href="https://www.corporateprofile.com/author/admin/" title="Posts by admin" rel="author">admin</a></h4></div></div></div><div class="kleanity-single-nav-area clearfix" ><span class="kleanity-single-nav kleanity-single-nav-left"><a href="https://www.corporateprofile.com/2013/12/23/implant-sciences-trace-detection-equipment-to-protect-2014-sochi-games/" rel="prev"><i class="arrow_left" ></i><span class="kleanity-text kleanity-title-font" >Prev</span></a></span><span class="kleanity-single-nav kleanity-single-nav-right"><a href="https://www.corporateprofile.com/2014/01/03/oramed-patent-allowance-in-israel-and-australia-for-platform-technology-in-oral-delivery-of-proteins/" rel="next"><span class="kleanity-text kleanity-title-font" >Next</span><i class="arrow_right" ></i></a></span></div> <div id="comments" class="kleanity-comments-area"> <div id="respond" class="comment-respond"> <h4 id="reply-title" class="comment-reply-title kleanity-content-font">Leave a Reply <small><a rel="nofollow" id="cancel-comment-reply-link" href="/2013/12/23/ormp-results-from-ex-us-pharmacokinetic-study-of-its-oral-insulin-for-type-1-diabetes/#respond" style="display:none;">Cancel Reply</a></small></h4> <form action="https://www.corporateprofile.com/wp-comments-post.php" method="post" id="commentform" class="comment-form" novalidate> <div class="comment-form-comment"><textarea id="comment" name="comment" cols="45" rows="8" aria-required="true" placeholder="Comment*" ></textarea></div><div class="comment-form-head"><div class="kleanity-comment-form-author" ><input id="author" name="author" type="text" value="" placeholder="Name*" size="30" aria-required='true' /></div> <div class="kleanity-comment-form-email" ><input id="email" name="email" type="text" value="" placeholder="Email*" size="30" aria-required='true' /></div> <input id="url" name="url" type="text" value="" placeholder="Website" size="30" /><div class="clear"></div></div> <p class="comment-form-cookies-consent"><input id="wp-comment-cookies-consent" name="wp-comment-cookies-consent" type="checkbox" value="yes" /><label for="wp-comment-cookies-consent">Save my name, email, and website in this browser for the next time I comment.</label></p> <p class="form-submit"><input name="submit" type="submit" id="submit" class="submit" value="Post Comment" /> <input type='hidden' name='comment_post_ID' value='5973' id='comment_post_ID' /> <input type='hidden' name='comment_parent' id='comment_parent' value='0' /> </p><p style="display: none;"><input type="hidden" id="akismet_comment_nonce" name="akismet_comment_nonce" value="6f9d97fa1d" /></p><p style="display: none;"><input type="hidden" id="ak_js" name="ak_js" value="155"/></p> </form> </div><!-- #respond --> </div><!-- kleanity-comments-area --></div></div></div></div></div><footer><div class="kleanity-footer-wrapper" ><div class="kleanity-footer-container kleanity-container clearfix" ><div class="kleanity-footer-column kleanity-item-pdlr kleanity-column-20" ><div id="text-6" class="widget widget_text kleanity-widget"><h3 class="kleanity-widget-title"><span class="kleanity-widget-head-text">Contact</span><span class="kleanity-widget-head-divider"></span></h3><span class="clear"></span> <div class="textwidget">Corporate Profile LLC<br /> 1185 Ave of the Americas 3rd Floor<br /> New York, NY 10036<br /> (212) 931-8787</div> </div></div><div class="kleanity-footer-column kleanity-item-pdlr kleanity-column-20" ></div><div class="kleanity-footer-column kleanity-item-pdlr kleanity-column-20" ></div></div></div><div class="kleanity-copyright-wrapper" ><div class="kleanity-copyright-container kleanity-container"><div class="kleanity-copyright-text kleanity-item-pdlr">Copyright © Corporate Profile<sup>®</sup>. All Rights Reserved. <a href="/about/disclaimer/">Disclaimer</a></div></div></div></footer></div></div> <!-- ngg_resource_manager_marker --><script>if (document.location.protocol != "https:") {document.location = document.URL.replace(/^http:/i, "https:");}</script><script type='text/javascript' src='https://www.corporateprofile.com/wp-content/plugins/goodlayers-core/plugins/combine/script.js?ver=5.0.22'></script> <script type='text/javascript'> /* <![CDATA[ */ var gdlr_core_pbf = {"admin":"","video":{"width":"640","height":"360"},"ajax_url":"https:\/\/www.corporateprofile.com\/wp-admin\/admin-ajax.php","ilightbox_skin":"dark"}; /* ]]> */ </script> <script type='text/javascript' src='https://www.corporateprofile.com/wp-content/plugins/goodlayers-core/include/js/page-builder.js?ver=1.3.9'></script> <script type='text/javascript' src='//www.corporateprofile.com/wp-content/plugins/revslider/sr6/assets/js/rbtools.min.js?ver=6.7.18'></script> <script type='text/javascript' src='//www.corporateprofile.com/wp-content/plugins/revslider/sr6/assets/js/rs6.min.js?ver=6.7.18'></script> <script type='text/javascript' src='https://maps.google.com/maps/api/js?libraries=geometry%2Cplaces%2Cweather%2Cpanoramio%2Cdrawing&language=en&ver=5.0.22'></script> <script type='text/javascript'> /* <![CDATA[ */ var wpgmp_local = {"all_location":"All","show_locations":"Show Locations","sort_by":"Sort by","wpgmp_not_working":"not working...","place_icon_url":"https:\/\/www.corporateprofile.com\/wp-content\/plugins\/wp-google-map-plugin\/assets\/images\/icons\/"}; /* ]]> */ </script> <script type='text/javascript' src='https://www.corporateprofile.com/wp-content/plugins/wp-google-map-plugin/assets/js/maps.js?ver=2.3.4'></script> <script type='text/javascript' src='https://www.corporateprofile.com/wp-includes/js/jquery/ui/effect.min.js?ver=1.11.4'></script> <script type='text/javascript'> /* <![CDATA[ */ var kleanity_script_core = {"home_url":"https:\/\/www.corporateprofile.com\/"}; /* ]]> */ </script> <script type='text/javascript' src='https://www.corporateprofile.com/wp-content/themes/kleanity/js/script-core.js?ver=1.0.0'></script> <script type='text/javascript' src='https://www.corporateprofile.com/wp-includes/js/comment-reply.min.js?ver=5.0.22'></script> <script type='text/javascript' src='https://www.corporateprofile.com/wp-includes/js/wp-embed.min.js?ver=5.0.22'></script> <script async="async" type='text/javascript' src='https://www.corporateprofile.com/wp-content/plugins/akismet/_inc/form.js?ver=4.1.1'></script> <script> window.RS_MODULES = window.RS_MODULES || {}; window.RS_MODULES.modules = window.RS_MODULES.modules || {}; window.RS_MODULES.waiting = window.RS_MODULES.waiting || []; window.RS_MODULES.defered = true; window.RS_MODULES.moduleWaiting = window.RS_MODULES.moduleWaiting || {}; window.RS_MODULES.type = 'compiled'; </script> <script></script> </body> </html>
